/Illumina%20biotechnology%20company%20displayed%20on%20mobile%20device%20By%20gguy.jpeg)
San Diego, California-based Illumina, Inc. (ILMN) provides sequencing- and array-based solutions for genetic and genomic analysis. Valued at $41.8 billion by market cap, the company also provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. The global leader in genomics is expected to announce its fiscal third-quarter earnings for 2026 after the market closes on Thursday, Oct. 29.
Ahead of the event, analysts expect Illumina to report a profit of $1.36 per share on a diluted basis, up 1.5% from $1.34 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
